SIRPA and neoplasm: Moreover, the anti-tumor functions of macrophages can be enhanced through nanobody-mediated blockade of the CD47/SIRPa pathway, reprogramming of macrophages from M2 to M1 phenotype and depletion of TAMs from the TME.